Literature DB >> 15203562

Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom.

Mariana Morena de Vieira Santos1, Reinaldo José da Silva, Márcia Guimarães da Silva, Denise Fecchio.   

Abstract

Snake venoms have been used as antineoplastic substances in several experimental models. We demonstrated in previous studies that Bothrops jararaca venom (BjV) induces inhibition of Ehrlich ascites tumor (EAT) growth accompanied by an increase of mononuclear (MN) leukocytes in all groups inoculated with EAT and/or venom. The objective of the present study was to characterize the subpopulations of MN leukocytes involved in the inhibition of EAT growth by treatment with BjV. Swiss mice were inoculated with 1.0x10(3) EAT cells by the intraperitoneal route and treated with 0.4 mg/kg of BjV by the same route (Group TV). Treatment was started 24 h after tumor cell inoculation and consisted of five intraperitoneal injections performed at 72 h intervals. After 2, 8 and 14 days, groups of animals were sacrificed and the number of B, TCD4 and TCD8 lymphocytes, macrophages and natural killer cells present in the peritoneal cavity was determined by flow cytometry. The control group consisted of animals inoculated with EAT and treated with 0.1 ml of saline under the same conditions as the experimental group (Group T). Two additional control groups consisted of animals not inoculated with EAT and treated with saline or venom. Data were analyzed statistically by the Kruskal-Wallis non-parametric test for independent samples. On the 2nd and 8th day we observed a difference between groups T and TV (group T > group TV) for all cell types, except natural killer cells, that only differed on the 2nd day. However, on the 14th day there was no difference in MN cells among groups. These data suggest that the inhibition of EAT is related to the toxic action of BjV on tumor cells and/or to the proteolytic effect of the venom on the mediators produced by the cells for growth modulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15203562      PMCID: PMC1781540          DOI: 10.1080/09629350410001664770

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  11 in total

1.  IFN-beta 2/IL-6 augments the activity of human natural killer cells.

Authors:  T A Luger; J Krutmann; R Kirnbauer; A Urbanski; T Schwarz; G Klappacher; A Köck; M Micksche; J Malejczyk; E Schauer
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

2.  Peritoneal macrophages and neoplastic cells. I. Macrophages activity induced by heavily-irradiated or heat-killed cancer cells.

Authors:  M L Sezzi; L Bellelli; A Nista
Journal:  Oncology       Date:  1972       Impact factor: 2.935

3.  Interleukin-6 enhances the induction of human lymphokine-activated killer cells.

Authors:  G Gallagher; W H Stimson; J Findlay; F al-Azzawi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.

Authors:  S Iho; H Y Shau; S H Golub
Journal:  Cell Immunol       Date:  1991-06       Impact factor: 4.868

5.  Number of macrophages and distribution of mitotic activity in regressing and progressing Moloney sarcomas.

Authors:  S W Russel; W F Doe; C G Cochrane
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

6.  IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells.

Authors:  M J Smyth; J R Ortaldo; W Bere; H Yagita; K Okumura; H A Young
Journal:  J Immunol       Date:  1990-08-15       Impact factor: 5.422

7.  Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors.

Authors:  S W Russell; W F Doe; A T McIntosh
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

8.  The in vivo anti-tumor effect of human recombinant interleukin-6.

Authors:  M Kitahara; S Kishimoto; T Hirano; T Kishimoto; M Okada
Journal:  Jpn J Cancer Res       Date:  1990-10

9.  Antitumor effect of Bothrops jararaca venom.

Authors:  Reinaldo J da Silva; Márcia G da Silva; Lízia C Vilela; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2002-04       Impact factor: 4.711

10.  Cytokine profile of Ehrlich ascites tumor treated with Bothrops jararaca venom.

Authors:  Reinaldo J da Silva; Márcia G da Silva; Lízia C Vilela; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2002-08       Impact factor: 4.711

View more
  2 in total

Review 1.  Antitumoral activity of snake venom proteins: new trends in cancer therapy.

Authors:  Leonardo A Calderon; Juliana C Sobrinho; Kayena D Zaqueo; Andrea A de Moura; Amy N Grabner; Maurício V Mazzi; Silvana Marcussi; Auro Nomizo; Carla F C Fernandes; Juliana P Zuliani; Bruna M A Carvalho; Saulo L da Silva; Rodrigo G Stábeli; Andreimar M Soares
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

Review 2.  Anticancer Activity of Toxins from Bee and Snake Venom-An Overview on Ovarian Cancer.

Authors:  Marius Alexandru Moga; Oana Gabriela Dimienescu; Cristian Andrei Arvătescu; Petru Ifteni; Liana Pleş
Journal:  Molecules       Date:  2018-03-19       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.